Weekly News Roundup 9/03/04
Custom Labeling and Assay Development Facility Opens in Mass.
A new custom labeling and assay development facility will open its doors this month in Bedford, Mass. The new 3,500-square foot site is the first U.S. location for Cisbio International, based in France. The Bedford facility will offer services for the labeling of proteins, peptides, oligonucleotides, or other biomolecules with various fluorophores and tags such as Cryptate, XL665, biotin, or DNP, as well as technical support for customers.
World's First Diagnostic Microarray
Affymetrix Inc., Santa Clara, Calif., announced what it claims is the world's first microarray instrument system for clinical diagnostics. The GeneChip System 3000Dx (GCS 3000Dx) is approved for in vitro diagnostic use in Europe, enabling clinical laboratories in Europe to analyze microarray diagnostics. In a partnership with Affymetrix, Roche Diagnostics will offer the AmpliChip CYP450 Test, a microarray, which looks for variations in the genes, CYP2D6 and CYP2C19, thought to affect the rate at which an individual metabolizes many common drugs. The GCS 3000Dx system comprises a GCS 3000Dx Scanner with AutoloaderDx, a fluidics station FS450Dx, and GCOSDx software.
Drug Research Center in China Adopts High Content Screening
The National Center for Drug Screening (NCDS) in Shanghai, China established a high content screening (HCS) program for high content cell-based assays in its drug discovery and development efforts. The HCS platform will be based on the ArrayScan HCS Reader from Cellomics Inc., Pittsburgh, PA, as well as its software and reagents. The NCDS, which focuses on major diseases that affect the Chinese population, such as cancer, central nervous system diseases, metabolic disorders, and infectious diseases, offers drug screening services and technical consultation to universities, research institutions, and commercial entities across China.
Metabolic Profiling Services Available
A new metabolic profiling service promises to help pharmaceutical companies and biomedical researchers accelerate the drug development and testing process, according to its developers, at SIDMAP (Stable Isotope-Based Dynamic Metabolic Profiling), Los Angeles. Developed at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, by SIDMAP cofounders, Laszlo Boros, MD, and Paul Lee, MD, the technology uses smartly labeled metabolic substrate molecules (tracers) to track disease-characteristic metabolic pathways, which, they say, provides a detailed understanding of human diseases and drug effects at the nano-scale level. The company will then analyze the data for pharmaceutical companies and biomedical researchers.
By Elizabeth Tolchin